Real-world outcomes after CAR T versus standard therapy in third-line or later relapsed or refractory follicular lymphoma in the United States
2026 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.31397853
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
2
Papers
0
Citations
0
h-index
0
i10-index
Philip K. Chan is an academic researcher.
https://doi.org/10.6084/m9.figshare.31397853
https://doi.org/10.6084/m9.figshare.31397853.v1
Click to start Chat